Omivera (CellEKT)

Omivera presents a revolutionary approach to kinase inhibitor screening, addressing a critical gap in the drug discovery process (CellEKT). Our technology is built on patented molecular probes that enable cellular-based assays with 90+% kinome coverage, overcoming limitations of traditional biochemical methods and enabling more accurate and comprehensive kinase profiling. We have validated the technology in a partnership with Roche by screening clinically used kinase inhibitors. Our cellular data showed to be much more predictive for the clinical outcome. This proves that using our cellular data translates to more reliable screening results for our clients, leading to quicker identification of promising drug candidates and accelerated development timelines.

Omivera is led by Joel Rüegger, inventor of the technology and currently postdoc at Leiden University, who is joined by Anthe Janssen (currently assistant professor in computational chemical biology at Leiden University), Zoë Vogelaar (business and law intern) and Alexander Turkin (business developer at Oncode Institute). Together, we have ample expertise in kinase biology, assay development and data analysis technologies, ensuring robust and reproducible data, as well as strong business know-how. In our ongoing partnership with Roche, we are expanding our technology towards even more biologically relevant systems such as organoids and in vivo mouse models. Our technology will also be expanded to cover more than the kinase family, securing a role in the broader drug development industry.

CellEKT will function as a CRO, entering the existing $350 million kinase screening market. Our aim is to achieve 1-2% market share in 5 years with our unique value offering. Our service-based model offers flexible engagement options, scaling from individual projects to long-term collaborations. CellEKT is committed to delivering high-quality, cost-effective solutions that empower our clients to make a real impact on patient health.